Supplementary Table 1. *Search Strategy*

PubMed: November 14, 2019

1. "cannabis use disorder"/4158
2. "pharmacotherapy"/3135179
3. 1 and 2/1028
4. Limit 3 to (Clinical Trial, Human population, and English Language)/100

MEDLINE: November 14, 2019

1. Exp cannabis dependence.mp. or exp Marijuana Abuse/6268
2. Exp pharmacotherapy.mp. or exp Drug Therapy/1346508
3. 1 and 2/298
4. Limit 3 to (English Language and Humans)/253

EMBASE: November 14, 2019

1. Exp cannabis addiction/9646
2. Exp pharmacotherapy.mp. or exp drug therapy/2796749
3. 1 and 2/1009
4. Limit 3 to (English Language and Humans)/929

PsycINFO: November 14, 2019

1. Exp Marijuana Usage or marijuana abuse.mp or cannabis dependence.mp or exp "Cannabis Use Disorder"/ or "cannabis use disorder"/6569
2. Exp pharmacotherapy.mp. or exp drug therapy/146907
3. 1 and 2/466
4. Limit 3 to (English Language and Humans)/432

Cochrane Central Register of Controlled Trials: November 14, 2019

1. Exp cannabis dependence.mp. or Marijuana Abuse/653
2. Exp pharmacotherapy.mp. or exp drug therapy/7331
3. 1 and 2/30

Supplementary Table 2. *Secondary outcomes*

Study	**Abstinence**	**Adverse events**	**Withdrawal Severity**	**Cravings Severity**	**CUD Severity**
Allsop 2014	Not reported	13/27 vs. 12/24	1.88 (1.64) vs. 2.22 (1.62)	1.87 (2.28) vs. 1.81 (2.26)	4.11 (5.29) vs. 4.04 (5.21)
Carpenter 2009	8/36 vs. 4/30	15/36 vs. 8/30	3.1 (1.9) vs. 1.9 (1.9)	Not reported	2.5 (1.4) vs. 2.3 (1.6)
Carpenter 2009b	4/40 vs. 4/30	18/40 vs. 8/30	4.0 (2.1) vs. 1.9 (1.9)	Not reported	2.7 (1.5) vs. 2.3 (1.6)
Cornelius 1999	Not reported	0/11 vs. 0/11	Not reported	Not reported	40.2 (8.5) vs. 47.5 (8.5)
Cornelius 2010	7/34 vs. 8/36	0/34 vs. 0/36	Not reported	Not reported	3.88 (2.51) vs. 3.61 (1.92
D'Souza 2019	Not reported	20/46 vs. 11/24	7.65 (1.32) vs. 9.04 (2.08)	Not reported	Not reported
Gray 2012	11/58 vs. 6/58	24/58 vs. 27/58	Not reported	Not reported	Not reported
Gray 2017	33/153 vs. 36/149	41/153 vs. 41/149	Not reported	Not reported	Not reported
Hill 2017	1/10 vs. 1/8	2/10 vs. 4/8	Not reported	51.7 (14) vs. 52.3 (10.4)	Not reported
Johnston 2014	6/16 vs. 6/22	12/16 vs. 14/22	1.24 (1.66) vs. 1.25 (1.97)	Not reported	3.07 (4.04) vs. 3.85 (3.91)
Levin 2004	6/13 vs. 5/12	3/13 vs. 1/12	19.22 (10.15) vs. 12.83 (10.22)	27.56 (36.71) vs. 16.83 (28.94)	Not reported
Levin 2011	14/79 vs. 12/77	53/79 vs. 45/77	4 (4.7) vs. 5 (5.4)	Not reported	Not reported
Levin 2013	6/51 vs. 19/52	51/51 vs. 29/52	Not reported	Not reported	Not reported
Levin 2016	17/61 vs. 19/61	47/61 vs. 46/61	4.8 (0.61) vs. 5.5 (0.77)	42.4 (16.9) vs. 40.1 (15.4)	Not reported
Lintzeris 2019	18/61 vs. 11/67	15/61 vs. 17/67	30.7 (28.9) vs. 43.6 (37.3)	27.2 (18.9) 31.2 (15.2)	Not reported
Mason 2012	Not reported	15/25 vs. 20/25	1.5 (1.0) vs. 0.4 (1.0)	0.2 (0.1) vs. 0.75 (0.3)	1.4 (1.6) vs. 1.6 (0.7)
McRae-Clark 2009	5/23 vs. 2/27	22/23 vs. 21/27	7.73 (8.99) vs. 7.00 (7.73)	19.95 (16.29) vs. 26.9 (15.75)	Not reported
McRae-Clark 2010	8/19 vs. 6/19	19/19 vs. 16/19	Not reported	25.51 (13.28) vs. 25.55 (15.97)	Not reported
McRae-Clark 2015	8/88 vs. 4/87	73/88 vs. 66/87	Not reported	46.4 (1.79) vs. 45.8 (1.48)	Not reported
McRae-Clark 2016	2/41 vs. 2/35	25/41 vs. 28/35	Not reported	49.9 (2.55) vs. 46.7 (0.11)	Not reported
Miranda 2017	Not reported	14/40 vs. 1/26	Not reported	Not reported	Not reported
Penetar 2012	Not reported	0/10 vs. 0/12	3.0 (0.51) vs. 4.1 (0.97)	1.2 (0.31) vs. 1.5 (0.26)	Not reported
Sherman 2017	0/8 vs. 0/8	1/8 vs. 2/8	Not reported	Not reported	Not reported
Trigo 2018	5/20 vs. 7/20	16/20 vs. 16/20	4.5 (0.6) vs. 4 (1)	7.0 (2.0) vs. 9.0 (2.0)	Not reported
Weinstein 2014	7/26 vs. 3/26	2/26 vs. 1/26	Not reported	Not reported	Not reported


Contrast to Placebo
Direct Comparisons
Random Effects Model
RR
95%-CI
P-Score
Nabilone 1.00 0.40 [0.10; 1.66] 0.89
Vilazodone 1.00 0.76 [0.57; 1.02] 0.83
Gabapentin 1.00 0.75 [0.52; 1.09] 0.83
Oxytocin 1.00 0.50 [0.06; 4.47] 0.76
N-acetylcysteine 2.00 0.94 [0.71; 1.23] 0.68
FAAH-inhibitor 1.00 0.95 [0.55; 1.64] 0.63
Nabiximols 3.00 0.99 [0.77; 1.26] 0.62
Dronabinol/Lofexidine 1.00 1.02 [0.84; 1.25] 0.58
Dronabinol 1.00 1.15 [0.90; 1.46] 0.44
Buspirone 2.00 1.14 [1.00; 1.29] 0.44
Lithium 1.00 1.18 [0.77; 1.80] 0.44
Atomoxetine 1.00 1.18 [0.98; 1.43] 0.40
Escitalopram 1.00 2.00 [0.19; 20.72] 0.34
Nefazodone 1.00 1.56 [0.77; 3.17] 0.29
Bupropion SR 1.00 1.69 [0.85; 3.35] 0.24
Divalproex Sodium 1.00 2.77 [0.33; 23.14] 0.24
Venlafaxine XR 1.00 1.78 [1.40; 2.26] 0.18
Topiramate 1.00 9.10 [1.27; 65.11] 0.04
0.1 0.5 1 2 10
Favors drug Favors placebo
Rate ratio for adverse events


Contrast to Placebo
Direct Comparisons
Random Effects Model
RR
95%-CI
P-Score
Nabiximols 2.00 0.33 [0.04; 3.09] 0.80
N-acetylcysteine 2.00 0.39 [0.07; 2.28] 0.78
Buspirone 2.00 0.63 [0.15; 2.60] 0.69
Bupropion SR 1.00 0.75 [0.05; 11.51] 0.63
Nefazodone 1.00 0.83 [0.05; 12.77] 0.60
Dronabinol 1.00 0.97 [0.06; 15.31] 0.57
Gabapentin 1.00 1.00 [0.07; 15.12] 0.57
Vilazodone 1.00 1.71 [0.16; 18.04] 0.45
Atomoxetine 1.00 3.00 [0.13; 69.20] 0.36
Divalproex Sodium 1.00 2.77 [0.33; 23.14] 0.34
Venlafaxine XR 1.00 5.10 [0.25; 103.61] 0.26
Dronabinol/Lofexidine 1.00 5.00 [0.60; 41.55] 0.23
Topiramate 1.00 9.10 [1.27; 65.11] 0.14
0.01 0.1 1 10 100
Favors drug Favors placebo
Rate ratio for losses due to adverse events


Contrast to Placebo
Direct Comparisons
Random Effects Model
SMD
95%-CI
P-Score
Dronabinol/Lofexidine 1.00 -1.00 [-2.37; 0.37] 0.84
FAAH-inhibitor 1.00 -0.85 [-2.26; 0.56] 0.79
Nabiximols 3.00 -0.39 [-1.21; 0.43] 0.66
Dronabinol 1.00 -0.20 [-1.55; 1.16] 0.56
Lithium 1.00 -0.01 [-1.47; 1.46] 0.48
Bupropion SR 2.00 0.02 [-1.04; 1.09] 0.46
Nefazodone 1.00 0.08 [-1.25; 1.40] 0.44
Buspirone 1.00 0.09 [-1.34; 1.51] 0.44
Divalproex Sodium 1.00 0.61 [-0.94; 2.15] 0.26
Gabapentin 1.00 1.08 [-0.36; 2.53] 0.12
-2 -1 0 1 2
Favors drug Favors placebo
Standardized mean difference for cannabis withdrawal


Contrast to Placebo
Direct Comparisons
Random Effects Model
SMD
95%-CI
P-Score
Gabapentin 1.00 -2.42 [-3.53; -1.32] 0.99
Bupropion SR 1.00 -1.02 [-2.24; 0.20] 0.82
Nabiximols 3.00 -0.36 [-0.92; 0.20] 0.66
Nabilone 1.00 -0.05 [-1.28; 1.19] 0.48
Atomoxetine 1.00 -0.00 [-1.04; 1.03] 0.46
Buspirone 2.00 0.02 [-0.64; 0.67] 0.44
Dronabinol/Lofexidine 1.00 0.14 [-0.75; 1.03] 0.38
Divalproex Sodium 1.00 0.31 [-0.82; 1.45] 0.32
Vilazodone 1.00 1.69 [0.71; 2.66] 0.01
-3 -2 -1 0 1 2 3
Favors drug Favors placebo
Standardized mean difference for cannabis cravings


Contrast to Placebo
Direct Comparisons
Random Effects Model
SMD
95%-CI
P-Score
Fluoxetine 2.00 -0.28 [-1.19; 0.64] 0.66
Lithium 1.00 -0.19 [-1.47; 1.09] 0.59
Gabapentin 1.00 -0.16 [-1.40; 1.08] 0.57
Nabiximols 1.00 0.01 [-1.22; 1.25] 0.47
Nefazodone 1.00 0.13 [-1.08; 1.34] 0.41
Bupropion SR 1.00 0.26 [-0.94; 1.47] 0.33
-1 -0.5 0 0.5 1
Favors drug Favors placebo
Standardized mean difference for CUD severity


Contrast to Placebo
Direct Comparisons
Random Effects Model
RR
95%-CI
P-Score
Venlafaxine XR 1.00 0.32 [0.11; 0.90] 0.93
Bupropion SR 1.00 0.75 [0.18; 3.16] 0.66
Dronabinol/Lofexidine 1.00 0.89 [0.39; 2.04] 0.62
Fluoxetine 1.00 0.93 [0.31; 2.75] 0.59
Vilazodone 1.00 0.85 [0.12; 6.33] 0.59
Nabilone 1.00 0.80 [0.05; 11.69] 0.59
Divalproex Sodium 1.00 1.11 [0.38; 3.26] 0.50
N-acetylcysteine 2.00 1.11 [0.60; 2.06] 0.50
Dronabinol 1.00 1.14 [0.45; 2.89] 0.49
Nabiximols 2.00 1.26 [0.62; 2.56] 0.43
Atomoxetine 1.00 1.33 [0.47; 3.79] 0.41
Lithium 1.00 1.38 [0.45; 4.19] 0.40
Nefazodone 1.00 1.67 [0.47; 5.86] 0.32
Escitalopram 1.00 2.33 [0.59; 9.29] 0.21
Buspirone 2.00 2.30 [0.82; 6.45] 0.18
0.1
0.5
1
2
10
Favors placebo
Favors drug
Rate ratio for abstinence

Supplementary Table 3. *Cochrane risk of bias tool results for individual studies. Colours indicate the risk of bias per study domain: green = low risk of bias; yellow = unclear risk of bias; and red = high risk of bias.*



Study	**Randomization**	**Allocation**	**Participant blinding**	**Assessment blinding**	**Attrition bias**	**Selective reporting**	**Other bias**	**The overall risk of bias**
Allsop 2014	Low risk	High risk	Low risk	Low risk	Low risk	High risk	Low risk	High risk
Carpenter 2009	Unclear risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Cornelius 1999	Low risk	High risk	Low risk	Low risk	Low risk	Low risk	High risk	Low risk
Cornelius 2010	Low risk	High risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
D'Souza 2019	Low risk	Low risk	Low risk	Low risk	High risk	Low risk	Low risk	Low risk
Gray 2012	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Gray 2017	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Hill 2017	Low risk	High risk	High risk	High risk	High risk	Low risk	Low risk	High risk
Johnston 2014	Unclear risk	Unclear risk	Low risk	Low risk	Low risk	Low risk	Unclear risk	Unclear risk
Levin 2004	Unclear risk	Unclear risk	Low risk	Low risk	High risk	Low risk	Low risk	Unclear risk
Levin 2011	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Levin 2013	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Levin 2016	Low risk	Low risk	Low risk	Low risk	High risk	Low risk	Low risk	Low risk
Lintzeris 2019	Low risk	Low risk	Low risk	Low risk	High risk	Low risk	Low risk	Low risk
Mason 2012	Low risk	Low risk	Low risk	Low risk	Unclear risk	Low risk	Low risk	Low risk
McRae-Clark 2009	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
McRae-Clark 2010	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
McRae-Clark 2015	Unclear risk	Unclear risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear risk
McRae-Clark 2016	Low risk	Unclear risk	Unclear risk	Unclear risk	Low risk	Low risk	High risk	Unclear risk
Miranda 2017	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Penetar 2012	Unclear risk	Unclear risk	Low risk	Low risk	High risk	Unclear risk	Low risk	Unclear risk
Sherman 2017	Unclear risk	Unclear risk	High risk	High risk	Low risk	High risk	Low risk	High risk
Trigo 2018	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Weinstein 2014	Unclear risk	Unclear risk	Low risk	Low risk	High risk	Low risk	Low risk	Unclear risk

Supplementary Table 4. *Funnel plots*






p = 0.06 (Egger)
p < 0.01 (Begg-Mazumdar)
p = 0.47 (Thompson-Sharp)
Standard Error
0.0
0.5
1.0
1.5
0.05
0.10
0.20
0.50
1.00
2.00
5.00
10.00
20.00
RR for losses due to adverse events


p = 0.40 (Egger)
p < 0.01 (Begg-Mazumdar)
p = 0.66 (Thompson-Sharp)
Standard Error
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.1
0.2
0.5
1.0
2.0
5.0
10.0
RR for abstinence


(Egger)
(Begg-Mazumdar)
(Thompson-Sharp)
Standard Error
0.0
0.1
0.2
0.3
0.4
-0.5
0.0
0.5
SMD for CUD symptoms


p = 0.11 (Egger)
p = 1.00 (Begg-Mazumdar)
p = 0.12 (Thompson-Sharp)
Standard Error
0.0
0.1
0.2
0.3
0.4
-0.5
0.0
0.5
1.0
SMD for cannabis cravings


p = 0.42 (Egger)
p = 0.21 (Begg-Mazumdar)
p = 0.18 (Thompson-Sharp)
Standard Error
0.0
0.1
0.2
0.3
0.4
0.5
-1.0
-0.5
0.0
0.5
1.0
SMD for cannabis withdrawal


p = 0.82 (Egger)
p < 0.01 (Begg-Mazumdar)
p = 0.96 (Thompson-Sharp)
Standard Error
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.1
0.2
0.5
1.0
2.0
5.0
10.0
RR for adverse events

Supplementary Table 5. Sensitivity analysis after removing the high risk of bias studies.

Cannabis use (*d*) vs. placebo	Nabiximols -1.45 [-3.32; 0.41] Fluoxetine -2.30 [-4.75; 0.15] **FAAH-inhibitor** -3.60 [-6.86; -0.35] **Nabilone** -4.47 [-8.15; -0.79] Lithium -0.43 [-3.65; 2.80] Gabapentin -0.88 [-4.09; 2.33] **Topiramate** -3.80 [-7.06; -0.54] Oxytocin 1.15 [-2.19; 4.48]
Retention in treatment (RR) vs. placebo	Nabiximols 1.15 [0.92; 1.42] Nefazodone 1.13 [0.69; 1.83] Bupropion SR 1.06 [0.67; 1.67] Fluoxetine 1.00 [0.89; 1.11] FAAH-inhibitor 0.99 [0.79; 1.24] N-acetylcysteine 1.06 [0.93; 1.21] Nabilone 0.80 [0.42; 1.52] Lithium 1.12 [0.79; 1.58] Divalproex Sodium 1.15 [0.40; 3.31] Dronabinol 1.27 [1.02; 1.57] Venlafaxine XR 0.96 [0.71; 1.30] Dronabinol/Lofexidine 0.88 [0.68; 1.15] Gabapentin 0.64 [0.30; 1.37] Buspirone 0.96 [0.74; 1.23] Atomoxetine 1.29 [0.60; 2.74] Vilazodone 0.70 [0.41; 1.21] **Topiramate** 0.62 [0.42; 0.91] Oxytocin 0.86 [0.53; 1.38] Escitalopram 0.62 [0.35; 1.11]
Treatment discontinuation (RR) vs. placebo	Nabiximols 0.88 [0.66; 1.19] Nefazodone 0.89 [0.57; 1.40] Bupropion SR 0.95 [0.65; 1.38] Fluoxetine 1.06 [0.23; 4.89] FAAH-inhibitor 1.04 [0.35; 3.12] N-acetylcysteine 0.87 [0.66; 1.15] Nabilone 1.60 [0.39; 6.62] Lithium 0.69 [0.20; 2.35] Divalproex Sodium 0.92 [0.51; 1.66] Dronabinol 0.58 [0.36; 0.96] Venlafaxine XR 1.07 [0.65; 1.76] Dronabinol/Lofexidine 1.26 [0.78; 2.05] Gabapentin 1.29 [0.84; 1.97] Buspirone 1.05 [0.80; 1.37] Atomoxetine 0.83 [0.48; 1.44] Vilazodone 1.28 [0.87; 1.89]

	Topiramate 2.28 [1.06; 4.87] Oxytocin 2.00 [0.22; 17.89] Escitalopram 1.60 [0.90; 2.84]
Discontinuation due to adverse events (RR) vs. placebo	Nabiximols 0.33 [0.04; 3.09] Nefazodone 0.83 [0.05; 12.77] Bupropion SR 0.75 [0.05; 11.51] N-acetylcysteine 0.39 [0.07; 2.28] Divalproex Sodium 2.77 [0.33; 23.14] Dronabinol 0.97 [0.06; 15.31] Venlafaxine XR 5.10 [0.25; 103.61] Dronabinol/Lofexidine 5.00 [0.60; 41.55] Gabapentin 1.00 [0.07; 15.12] Buspirone 0.63 [0.15; 2.60] Atomoxetine 3.00 [0.13; 69.20] Vilazodone 1.71 [0.16; 18.04] **Topiramate** 9.10 [1.27; 65.11]
Cannabis withdrawal (*d*) vs. placebo	Nabiximols -0.39 [-1.21; 0.43] Nefazodone 0.08 [-1.25; 1.40] Bupropion SR 0.02 [-1.04; 1.09] FAAH-inhibitor -0.85 [-2.26; 0.56] Lithium -0.01 [-1.47; 1.46] Divalproex Sodium 0.61 [-0.94; 2.15] Dronabinol -0.20 [-1.55; 1.16] Dronabinol/Lofexidine -1.00 [-2.37; 0.37] Gabapentin 1.08 [-0.36; 2.53] Buspirone 0.09 [-1.34; 1.51]
Cannabis cravings (*d*) vs. placebo	Nabiximols -0.36 [-0.92; 0.20] Bupropion SR -1.02 [-2.24; 0.20] Nabilone -0.05 [-1.28; 1.19] Divalproex Sodium 0.31 [-0.82; 1.45] Dronabinol/Lofexidine 0.14 [-0.75; 1.03] **Gabapentin** -2.42 [-3.53; -1.32] Buspirone 0.02 [-0.64; 0.67] Atomoxetine -0.00 [-1.04; 1.03] Vilazodone 1.69 [0.71; 2.66]
Cannabis use disorder symptoms (*d*) vs. placebo	Nabiximols 0.01 [-1.22; 1.25] Nefazodone 0.13 [-1.08; 1.34] Bupropion SR 0.26 [-0.94; 1.47] Fluoxetine -0.28 [-1.19; 0.64] Lithium -0.19 [-1.47; 1.09] Gabapentin -0.16 [-1.40; 1.08]
Adverse events (RR) vs. placebo	Nabiximols 0.99 [0.77; 1.26] Nefazodone 1.56 [0.77; 3.17] Bupropion SR 1.69 [0.85; 3.35] FAAH-inhibitor 0.95 [0.55; 1.64] N-acetylcysteine 0.94 [0.71; 1.23]

	Nabilone 0.40 [0.10; 1.66] Lithium 1.18 [0.77; 1.80] Divalproex Sodium 2.77 [0.33; 23.14] Dronabinol 1.15 [0.90; 1.46] Venlafaxine XR 1.78 [1.40; 2.26] Dronabinol/Lofexidine 1.02 [0.84; 1.25] Gabapentin 0.75 [0.52; 1.09] Buspirone 1.14 [1.00; 1.29] Atomoxetine 1.18 [0.98; 1.43] Vilazodone 0.76 [0.57; 1.02] Topiramate 9.10 [1.27; 65.11] Oxytocin 0.50 [0.06; 4.47] Escitalopram 2.00 [0.19; 20.72]
Abstinence (RR) vs. placebo	Nabiximols 1.26 [0.62; 2.56] Nefazodone 1.67 [0.47; 5.86] Bupropion SR 0.75 [0.18; 3.16] Fluoxetine 0.93 [0.31; 2.75] N-acetylcysteine 1.11 [0.60; 2.06] Nabilone 0.80 [0.05; 11.69] Lithium 1.37 [0.45; 4.19] Divalproex Sodium 1.11 [0.38; 3.26] Dronabinol 1.14 [0.45; 2.89] Venlafaxine XR 0.32 [0.11; 0.90] Dronabinol/Lofexidine 0.89 [0.39; 2.04] Buspirone 2.30 [0.82; 6.45] Atomoxetine 1.33 [0.47; 3.79] Vilazodone 0.85 [0.12; 6.33] Escitalopram 2.33 [0.59; 9.29]

Supplementary Table 6. Medications included in this analysis and their current medical use

Agent	Mechanism of action	Clinical use
Nabiximols	A mixture of tetrahydrocannabinol (THC) and cannabidiol (CBD)	Spasticity in multiple sclerosis
Nefazodone	Serotonin antagonist and reuptake inhibitor (SARI)	Antidepressant
Bupropion sustained-release	Noradrenergic and dopaminergic reuptake inhibitor (NDRI)	Antidepressant, smoking cessation, attention-deficit hyperactivity disorder (ADHD)
Fluoxetine	Selective serotonin reuptake inhibitor (SSRI)	Antidepressant, anxiolytic
N-acetylcysteine	Glutathione precursor, role in glutamatergic neurotransmission	Acetaminophen overdose, treatment of several psychiatric disorders
Nabilone	Synthetic cannabinoid	Antiemetic, analgesic, nightmares in post-traumatic stress disorder
Lithium	Unclear, but appears to modulate secondary messenger systems	Mood stabilizer in bipolar disorder, augmentation agent in depression
Divalproex	An antagonist of the voltage-gated sodium channel that enhances gamma-aminobutyric acid (GABA) neurotransmission	Anticonvulsant, mood-stabilizing agent, anti-migraine agent
Dronabinol	Synthetic cannabinoid	Antiemetic, analgesic, appetite stimulant
Venlafaxine extended-release	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Antidepressant, anxiolytic, analgesic for neuropathic pain
Lofexidine	α_{2A} adrenergic receptor agonist	Opioid withdrawal, hypertension
Buspirone	Non-benzodiazepine anxiolytic	Anxiety disorders
Atomoxetine	Noradrenergic reuptake inhibitor (NRI)	ADHD
Vilazodone	Serotonin reuptake inhibitor and 5-HT_{1A} receptor partial agonist	Antidepressant
Escitalopram	Selective serotonin reuptake inhibitor (SSRI)	Antidepressant, anxiolytic